References
1. National ENTTRN. The British Rhinological Society multidisciplinary consensus recommendations on the hospital management of epistaxis. J Laryngol Otol 2017; 131:1142-1156.
2. Escabasse V, Bequignon E, Verillaud Bet al. Guidelines of the French Society of Otorhinolaryngology (SFORL). Managing epistaxis under coagulation disorder due to antithrombotic therapy. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134:195-199.
3. Garneau JC, Wasserman I, Konuthula N, Malkin BD. Referral patterns from emergency department to otolaryngology clinic. Laryngoscope 2018; 128:1062-1067.
4. Tunkel DE, Anne S, Payne SCet al. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngol Head Neck Surg 2020; 162:S1-S38.
5. Nikolaou G, Holzmann D, Soyka MB. Discomfort and costs in epistaxis treatment. Eur Arch Otorhinolaryngol 2013; 270:2239-2244.
6. Althaus AE, Luske J, Arendt Uet al. Treating epistaxis - who cares for a bleeding nose? A secondary data analysis of primary and secondary care. BMC Fam Pract 2021; 22:75.
7. Runggaldier D, Schindler V, Luo Y, Kleinjung T, Soyka MB. Novel oral anticoagulation treatment is not associated with recurrent or severe epistaxis. Rhinology 2021; 59:219-221.
8. Yaniv D, Zavdy O, Sapir E, Levi L, Soudry E. The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis. Laryngoscope 2021.
9. Kallenbach M, Dittberner A, Boeger Det al. Hospitalization for epistaxis: a population-based healthcare research study in Thuringia, Germany. Eur Arch Otorhinolaryngol 2020; 277:1659-1666.
10. Althaus AE, Arendt U, Hoffmann Fet al. [Epistaxis and anticoagulation therapy: an analysis based on health insurance data from Lower Saxony]. HNO 2021; 69:206-212.
11. Hindricks G, Potpara T, Dagres Net al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42:373-498.
12. Ortel TL, Neumann I, Ageno Wet al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4:4693-4738.
13. Stankovic P, Georgiew R, Frommelt Cet al. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon. J Thromb Thrombolysis 2019; 47:384-391.
14. Page MJ, McKenzie JE, Bossuyt PMet al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:n71.
15. FDA Approval Dabigatran. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000toc.cfm. Accessed 26.04.2021.
16. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73:712-716.
17. L’Huillier V, Badet C, Tavernier L. Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. Eur Ann Otorhinolaryngol Head Neck Dis 2018; 135:231-235.
18. Gokdogan O, Akyildiz I, Sayin BY, Okutucu S, Tanalp AC, Arslan N. The Rate of Epistaxis Incidence in New-Generation Anticoagulants and Perioperative Approach in Otorhinolaryngological Practices. J Craniofac Surg 2017; 28:e178-e182.
19. García Callejo FJ, Bécares Martínez C, Calvo González J, Martínez Beneyto P, Marco Sanz M, Marco Algarra J. Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Acta Otorrinolaringol Esp 2014; 65:346–354.
20. Send T, Bertlich M, Horlbeck Fet al. Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin. Int Forum Allergy Rhinol 2019; 9:120-124.
21. Buchberger AMS, Baumann A, Johnson Fet al. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol 2018; 275:2035-2043.
22. Glikson E, Chavkin U, Madgar Oet al. Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents. Laryngoscope 2019; 129:119-123.
23. Sauter TC, Hegazy K, Hautz WEet al. Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clin Otolaryngol 2018; 43:103-108.
24. Davies T, Alatsatianos A, Slim MAM, Royce W, Whymark A. The impact of frailty on epistaxis admission, a retrospective cohort study. Clin Otolaryngol 2021.
25. Sethi RKV, Kozin ED, Abt NB, Bergmark R, Gray ST. Treatment disparities in the management of epistaxis in United States emergency departments. Laryngoscope 2018; 128:356-362.
26. Cooper SE, Ramakrishnan VR. Direct cauterization of the nasal septal artery for epistaxis. Laryngoscope 2012; 122:738-740.
27. Fleck R.A., Rao M., Rapaport S., N. V. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thrombosis Research 1990; 59:421-437.
28. Thornton MA, Mahesh BN, Lang J. Posterior epistaxis: identification of common bleeding sites. Laryngoscope 2005; 115:588-590.
29. Kawabori M, Niiya Y, Iwasaki Met al. Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin. Journal of Stroke and Cerebrovascular Diseases 2018; 27:1338-1342.
30. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm 2015; 37:53-59.
31. Merli GJ, Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis 2009; 27:293-299.
32. Neshewat J, Wasserman A, Alexandris-Souphis Cet al. Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program. Thromb Res 2021; 199:119-122.
33. Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart 2020; 106:10-17.